Posted by Michael Wonder on 22 Nov 2019
Revised process for cell and gene therapies
21 November 2019 - CADTH has undertaken an internal review and established a novel process for the review of cell and gene therapies.
This new process will offer stakeholders the benefits of firm performance targets and well-established methods for conducting reviews and issuing recommendations for drug products, with the additional ethical and implementation considerations that are an important strength of CADTH’s medical devices programs.
Complete details of the new process for the submission and review of cell and gene therapies will be announced in the near future.
